{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:33:49Z","timestamp":1794249229056,"version":"4.9.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.critrevonc.2020.103036","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T16:04:13Z","timestamp":1593187453000},"page":"103036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-9179","authenticated-orcid":false,"given":"Cristian","family":"Lolli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Altavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.103036_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2018.36.6_suppl.577","article-title":"Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): results from the NIVOREN GETUG-AFU 26 study","volume":"36","author":"Albiges","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0010","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/jco.2014.32.15_suppl.5010","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Amin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4505","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0020","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1158\/1078-0432.CCR-17-3436","article-title":"Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 study","volume":"24","author":"Atkins","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103036_bib0030","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","article-title":"Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells","volume":"101","author":"Brenchley","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jgo.2014.01.007","article-title":"Cancer in the elderly: is it time for palliative care in geriatric oncology?","volume":"5","author":"Brighi","year":"2014","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.11.010","article-title":"Immune checkpoint blockade for non-small cell lung cancer: what is the role in the special populations?","volume":"125","author":"Califano","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103036_bib0045","series-title":"Kidney Cancer Incidence Statistics","author":"Cancer Research UK","year":"2020"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103036_bib0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/09513590.2013.852531","article-title":"The immune system and aging: a review","volume":"30","author":"Castelo-Branco","year":"2014","journal-title":"Gynecol. Endocrinol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103036_bib0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0060","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103036_bib0065","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103036_bib0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clim.2007.12.002","article-title":"T cell subset-specific susceptibility to aging","volume":"127","author":"Czesnikiewicz-Guzik","year":"2008","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103036_bib0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bju.14461","article-title":"Italian Nivolumab Renal Cell Cancer Early Access Program Group. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme","volume":"123","author":"De Giorgi","year":"2018","journal-title":"BJU Int."},{"issue":"13","key":"10.1016\/j.critrevonc.2020.103036_bib0080","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-18-3661","article-title":"Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab","volume":"25","author":"De Giorgi","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0085","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clim.2006.09.012","article-title":"Peripheral blood dendritic cells and monocytes are differently regulated in the elderly","volume":"122","author":"Della Bella","year":"2007","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0008-8749(83)90237-X","article-title":"The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity","volume":"81","author":"Effros","year":"1983","journal-title":"Cell. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2020.103036_bib0095","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1473-3099(02)00437-1","article-title":"Ageing and infection","volume":"2","author":"Gavazzi","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0100","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.4049\/jimmunol.1500046","article-title":"Naive T cell maintenance and function in human aging","volume":"194","author":"Goronzy","year":"2015","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0105","first-page":"73","article-title":"Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities","volume":"22","author":"Graves","year":"2013","journal-title":"Immunotargets Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103036_bib0110","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.exger.2007.12.006","article-title":"CD95-mediated apoptosis in na\u00efve, central and effector memory subsets of CD4+ and CD8+ T cells in aged humans","volume":"43","author":"Gupta","year":"2008","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","author":"Hammers","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103036_bib0120","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/eji.201445312","article-title":"Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways","volume":"45","author":"Henson","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103036_bib0125","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.1992.10.7.1124","article-title":"A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma","volume":"10","author":"Ilson","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103036_bib0130","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.171.7.3353","article-title":"Cuttine edge: T cells from aged mice are resistant to depletion early during virus infection","volume":"171","author":"Jiang","year":"2003","journal-title":"J. Immunol."},{"issue":"suppl; abstr 4560","key":"10.1016\/j.critrevonc.2020.103036_bib0135","article-title":"Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results","volume":"36","author":"Lee","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"15 Supplement","key":"10.1016\/j.critrevonc.2020.103036_bib0140","article-title":"Immune checkpoint protein expression is up-regulated in tumor-bearing elderly mice","volume":"75","author":"Lim","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103036_bib0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0150","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0155","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"suppl; abstr 4500","key":"10.1016\/j.critrevonc.2020.103036_bib0160","article-title":"Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427","volume":"36","author":"McDermott","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0165","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S1470-2045(18)30952-5","article-title":"Modulating the microbiome to improve therapeutic response in cancer","volume":"20","author":"McQuade","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.0105-2896.2005.00263.x","article-title":"Effects of aging on early B- and T-cell development","volume":"205","author":"Min","year":"2005","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103036_bib0175","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","article-title":"Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up","volume":"11","author":"Minasian","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103036_bib0180","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1200\/JCO.1995.13.8.1950","article-title":"Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro","volume":"13","author":"Motzer","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2020.103036_bib0185","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"Engl. J.Med."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0195","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J.Med."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0200","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0205","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103036_bib0210","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0215","series-title":"Cancer Stat Facts: Kidney and Renal Pelvis Cancer","author":"National Cancer Institute","year":"2020"},{"key":"10.1016\/j.critrevonc.2020.103036_bib0220","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.4049\/jimmunol.174.11.7446","article-title":"The influence of age on T cell generation and TCR diversity","volume":"174","author":"Naylor","year":"2005","journal-title":"J. Immunol."},{"issue":"18","key":"10.1016\/j.critrevonc.2020.103036_bib0225","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran\u00e7ais d\u2019Immunoth\u00e9rapie","volume":"338","author":"Negrier","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0235","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","article-title":"Age and immunity: What is \u201cimmunosenescence\u201d?","volume":"105","author":"Pawelec","year":"2018","journal-title":"Exp. Gerontol."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.critrevonc.2010.06.012","article-title":"Immunosenescence and cancer","volume":"75","author":"Pawelec","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0245","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1354.018","article-title":"Naive T cells in the elderly: are they still there?","volume":"1067","author":"Pfister","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2020.103036_bib0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0531-5565(99)00089-3","article-title":"Surface markers and transendothelial migration of dendritic cells from elderly subjects","volume":"35","author":"Pietschmann","year":"2000","journal-title":"Exp. Gerontol."},{"issue":"9807","key":"10.1016\/j.critrevonc.2020.103036_bib0255","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"10189","key":"10.1016\/j.critrevonc.2020.103036_bib0260","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2020.103036_bib0265","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103036_bib0270","first-page":"217","article-title":"Immunity, autoimmunity and autoimmune diseases in older people","volume":"22","author":"Rosato","year":"2008","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103036_bib0275","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-3083.2002.01148.x","article-title":"Circulating, interferon-producing plasmacytoid dendritic cells decline during human ageing","volume":"56","author":"Shodell","year":"2002","journal-title":"Scand. J. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2020.103036_bib0280","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103036_bib0285","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-3083.2002.01068.x","article-title":"Age-related changes in human blood dendritic cell subpopulations","volume":"55","author":"Teig","year":"2002","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0290","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.103036_bib0295","article-title":"Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma","author":"Varkaris","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2020.103036_bib0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199642","article-title":"Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy","volume":"13","author":"Vitale","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103036_bib0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010038","article-title":"Gut microbiota and Cancer: from pathogenesis to therapy","volume":"11","author":"Vivarelli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2020.103036_bib0310","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"1997","journal-title":"J. Immunother."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820301748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820301748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:36:18Z","timestamp":1760902578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820301748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":62,"alternative-id":["S1040842820301748"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103036","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103036"}}